Skip to main content
Top
Published in: Supportive Care in Cancer 11/2022

21-03-2022 | Cannabinoid | Letter to the Editor

Comment on: Cannabis use among Danish patients with cancer: a cross‑sectional survey of sociodemographic traits, quality of life, and patient experiences

Authors: Luis Vitetta, Jason F. Sikali, Courtney Fletcher, Jeremy D. Henson

Published in: Supportive Care in Cancer | Issue 11/2022

Login to get access

Excerpt

The recent article by Nielsen and colleagues [1] presents an interesting cross-sectional investigation on a subgroup of cancer patients that self-prescribed cannabinoids. The authors present a study with a high response rate (83%) among the 326 patients (13% of the total cohort) that had used a cannabis-based medicine. Notwithstanding the small sample size, it still constitutes an evaluable response rate, given that the use of cannabis for medicinal purposes in Denmark is permitted. …
Literature
1.
go back to reference Nielsen SW, Ruhlmann CH, Eckhoff L, Brønnum D, Herrstedt J, Dalton SO (2022) Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. Support Care Cancer 30(2):1181–1190CrossRefPubMed Nielsen SW, Ruhlmann CH, Eckhoff L, Brønnum D, Herrstedt J, Dalton SO (2022) Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. Support Care Cancer 30(2):1181–1190CrossRefPubMed
2.
go back to reference Malhotra P, Casari I, Falasca M (2021) Therapeutic potential of cannabinoids in combination cancer therapy. Adv Biol Regul 79:100774CrossRefPubMed Malhotra P, Casari I, Falasca M (2021) Therapeutic potential of cannabinoids in combination cancer therapy. Adv Biol Regul 79:100774CrossRefPubMed
3.
go back to reference Jeffers AM, Glantz S, Byers A, Keyhani S (2021) Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US. JAMA Netw Open 4(11):e2136571CrossRefPubMedPubMedCentral Jeffers AM, Glantz S, Byers A, Keyhani S (2021) Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US. JAMA Netw Open 4(11):e2136571CrossRefPubMedPubMedCentral
6.
go back to reference Meng H, Page MG, Ajrawat P et al (2021) Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. Can J Anaesth 68(5):633–644CrossRefPubMed Meng H, Page MG, Ajrawat P et al (2021) Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients. Can J Anaesth 68(5):633–644CrossRefPubMed
7.
go back to reference Dryburgh LM, Bolan NS, Grof CPL et al (2018) Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol 84(11):2468–2476CrossRefPubMedPubMedCentral Dryburgh LM, Bolan NS, Grof CPL et al (2018) Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects. Br J Clin Pharmacol 84(11):2468–2476CrossRefPubMedPubMedCentral
8.
go back to reference Vitetta L, Sikali JF (2021) Comment on: Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in patients with chronic pain. Can J Anaesth 68(11):1707–1708CrossRefPubMed Vitetta L, Sikali JF (2021) Comment on: Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in patients with chronic pain. Can J Anaesth 68(11):1707–1708CrossRefPubMed
9.
go back to reference Hammond D (2021) Communicating THC levels and “dose” to consumers: implications for product labelling and packaging of cannabis products in regulated markets. Int J Drug Policy 91:102509CrossRefPubMed Hammond D (2021) Communicating THC levels and “dose” to consumers: implications for product labelling and packaging of cannabis products in regulated markets. Int J Drug Policy 91:102509CrossRefPubMed
10.
go back to reference Pusiak RJ, Cox C, Harris CS (2021) Growing pains: an overview of cannabis quality control and quality assurance in Canada. Int J Drug Policy 93:103111CrossRefPubMed Pusiak RJ, Cox C, Harris CS (2021) Growing pains: an overview of cannabis quality control and quality assurance in Canada. Int J Drug Policy 93:103111CrossRefPubMed
11.
go back to reference Weiss GA, Hennet T (2017) Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci 74(16):2959–2977CrossRefPubMed Weiss GA, Hennet T (2017) Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci 74(16):2959–2977CrossRefPubMed
12.
go back to reference Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109(40):E2657-2664CrossRefPubMedPubMedCentral Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109(40):E2657-2664CrossRefPubMedPubMedCentral
13.
go back to reference Goldenberg M, Danovitch I, IsHak WW (2014) Quality of life and smoking. Am J Addict 23(6):540–562CrossRefPubMed Goldenberg M, Danovitch I, IsHak WW (2014) Quality of life and smoking. Am J Addict 23(6):540–562CrossRefPubMed
14.
go back to reference Sexton M, Garcia JM, Jatoi A, Clark CS, Wallace MS (2021) The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids. J Natl Cancer Inst Monogr 2021(58):86–98CrossRefPubMedPubMedCentral Sexton M, Garcia JM, Jatoi A, Clark CS, Wallace MS (2021) The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids. J Natl Cancer Inst Monogr 2021(58):86–98CrossRefPubMedPubMedCentral
Metadata
Title
Comment on: Cannabis use among Danish patients with cancer: a cross‑sectional survey of sociodemographic traits, quality of life, and patient experiences
Authors
Luis Vitetta
Jason F. Sikali
Courtney Fletcher
Jeremy D. Henson
Publication date
21-03-2022
Publisher
Springer Berlin Heidelberg
Keyword
Cannabinoid
Published in
Supportive Care in Cancer / Issue 11/2022
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-022-06995-7

Other articles of this Issue 11/2022

Supportive Care in Cancer 11/2022 Go to the issue
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare